Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia

ClinicalTrials.gov ID: NCT07227818

Public ClinicalTrials.gov record NCT07227818. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 17, 2026, 6:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Assess the Efficacy of NBI-1117568 in Preventing Relapse of the Symptoms of Schizophrenia and to Assess the Safety and Tolerability of NBI-1117568 in Adults With Schizophrenia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main objective of the study is to evaluate NBI-1117568 compared with placebo in delaying relapse of symptoms of schizophrenia in adults who have a stable response after open-label treatment with NBI-1117568.

Study identification

NCT ID: NCT07227818
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Neurocrine Biosciences; Industry
Enrollment: 560 participants

Conditions and interventions

Conditions

Schizophrenia

Interventions

NBI-1117568 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 65 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 16, 2025 (Actual)
Primary completion: Jul 2029 (Estimated)
Completion: Jul 2029 (Estimated)
Last update posted: Sep 25, 2026

2025 – 2029

United States locations

U.S. sites: 22
U.S. states: 9
U.S. cities: 20

Facility	City	State	ZIP	Site status
Neurocrine Clinical Site	Garden Grove	California	92845	Recruiting
Neurocrine Clinical Site	La Habra	California	90631	Recruiting
Neurocrine Clinical Site	Lemon Grove	California	91945	Recruiting
Neurocrine Clinical Site	Oceanside	California	92056	Recruiting
Neurocrine Clinical Site	Torrance	California	90504	Recruiting
Neurocrine Clinical Site	West Hills	California	91307	Completed
Neurocrine Clinical Site	Hollywood	Florida	33024	Recruiting
Neurocrine Clinical Site	Maitland	Florida	32751	Recruiting
Neurocrine Clinical Site	Miami	Florida	33122	Recruiting
Neurocrine Clinical Site	Miami	Florida	33155	Recruiting
Neurocrine Clinical Site	Tampa	Florida	33629	Recruiting
Neurocrine Clinical Site	West Palm Beach	Florida	33024	Recruiting
Neurocrine Clinical Site	Atlanta	Georgia	30318	Recruiting
Neurocrine Clinical Site	Boston	Massachusetts	02116	Recruiting
Neurocrine Clinical Site	Flowood	Mississippi	39232	Recruiting
Neurocrine Clinical Site	Marlton	New Jersey	08054	Recruiting
Neurocrine Clinical Site	Cedarhurst	New York	11516	Recruiting
Neurocrine Clinical Site	New York	New York	10029	Recruiting
Neurocrine Clinical Site	New York	New York	10032	Withdrawn
Neurocrine Clinical Site	The Bronx	New York	10461	Recruiting
Neurocrine Clinical Site	DeSoto	Texas	75115	Recruiting
Neurocrine Clinical Site	Bellevue	Washington	98007	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07227818, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 25, 2026 · Synced Oct 17, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT07227818 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →